Study guide

1.4 Maternal Cardiac and Respiratory Disorders

NCC Inpatient Obstetric Nursing RNC-OB

Track your progress as you read

Finished sections get a check mark.

1 Chapter 0: Introduction & How to Use This Guide

0.1 About the RNC-OB Credential & Exam Blueprint 0.2 How to Use This Study Guide & Clinical Learning Methodology

2 Chapter 1: Pregnancy Complications — Maternal Medical Conditions

1.1 Hypertensive Disorders of Pregnancy 1.2 HELLP Syndrome & Hepatic Disorders of Pregnancy 1.3 Diabetes Mellitus in Pregnancy 1.4 Maternal Cardiac and Respiratory Disorders 1.5 Infectious Diseases in Inpatient Obstetrics 1.6 Hematologic, Endocrine, Connective Tissue & Other Systemic Disorders

3 Chapter 2: Pregnancy Complications — Preterm Labor, Multiple Gestation, Placental & Fetal Disorders

2.1 Psychosocial Disorders, Substance Use & Environmental Exposures 2.2 Preterm Labor: Assessment, Tocolysis & Neuroprotection 2.3 Multiple Gestation: Placentation, Chorionicity & Complications 2.4 Placental Disorders: Previa, Abruption, Vasa Previa & PAS 2.5 Fetal Growth Disorders & Amniotic Fluid Complications

4 Chapter 3: Antenatal Fetal Assessment & Surveillance

3.1 Antenatal Testing Methods & Indications for Fetal Surveillance 3.2 Nonstress Test (NST), Contraction Stress Test (CST) & Biophysical Profile (BPP) 3.3 Diagnostic Prenatal Procedures (Amniocentesis, CVS, PUBS, cfDNA & Ultrasound) 3.4 Fetal Oxygenation Physiology & Acid-Base Regulation 3.5 Umbilical Cord Blood Gas Collection & Clinical Interpretation

5 Chapter 4: Fetal Assessment & Electronic Fetal Monitoring (EFM)

4.1 NICHD Electronic Fetal Monitoring Terminology & Baseline Features 4.2 FHR Decelerations, Acceleration Patterns & Uterine Activity 4.3 The NICHD Three-Tier Fetal Heart Rate Classification System 4.4 Intrauterine Resuscitation & Clinical Action Protocols 4.5 Fetal Arrhythmias, Dysrhythmias & Artifact Differentiation

6 Chapter 5: Labor & Birth Physiology — Mechanics, Cardinal Movements, Stages & Support

5.1 Physiology of Labor & Uterine Mechanics 5.2 Pelvic Anatomy, Fetal Lie, Presentation & Cardinal Movements of Labor 5.3 Stages of Labor, Cervical Dilatation Dynamics & Progression Guidelines 5.4 Intrapartum Admission Assessment, Obstetric Triage & Membrane Rupture Evaluation 5.5 Labor Support, Non-Pharmacologic Pain Management & Physiologic Birth Practices

7 Chapter 6: Labor & Birth Interventions — Cervical Ripening, Induction, Pain Management & Anesthesia

6.1 Bishop Scoring, Pre-Induction Cervical Ripening & Mechanical Methods 6.2 Oxytocin Administration, Titration Protocols & Uterine Tachysystole Management 6.3 Nonpharmacologic Comfort & Labor Pain Management Strategies 6.4 Systemic Opioid Analgesia & Inhaled Nitrous Oxide 6.5 Neuraxial Analgesia, Spinal/Epidural Complications & General Anesthesia

8 Chapter 7: Labor & Birth — Operative Deliveries, TOLAC/VBAC & Special Intrapartum Procedures

7.1 External Cephalic Version (ECV) & Malpresentation Management 7.2 Operative Vaginal Delivery: Vacuum Extraction & Forceps-Assisted Birth 7.3 Cesarean Delivery: Surgical Indications, Intraoperative Management & PACU Recovery 7.4 Trial of Labor After Cesarean (TOLAC) & Vaginal Birth After Cesarean (VBAC) 7.5 Special Intrapartum Procedures: Amniotomy, Amnioinfusion, Cervical Ripening & Labor Augmentation

9 Chapter 8: Obstetric Emergencies & Critical Care

8.1 Shoulder Dystocia Management & HELPERR Protocol 8.2 Umbilical Cord Prolapse & Feto-Vascular Emergencies 8.3 Uterine Rupture & Acute Uterine Inversion 8.4 Amniotic Fluid Embolism (Anaphylactoid Syndrome of Pregnancy) 8.5 Intraamniotic Infection (Chorioamnionitis) & Maternal Sepsis

10 Chapter 9: Postpartum Physiology & Immediate Recovery Care

9.1 Postpartum Physiologic Changes & Maternal Systemic Adaptations 9.2 Fourth Stage of Labor & Immediate Recovery Care 9.3 Routine Postpartum Nursing Assessment & Clinical Care (BUBBLE-HE) 9.4 Rh Isoimmunization, Alloimmunization & Postpartum Immunizations 9.5 Postpartum Discharge Teaching, Warning Signs & Maternal Safety

11 Chapter 10: Postpartum Adaptation, Hemorrhage & Clinical Complications

10.1 Postpartum Hemorrhage: Definition, Risk Stratification, 4 Ts, QBL & Pharmacotherapy 10.2 Postpartum Infections: Endometritis, Wound Infections, Sepsis & Postpartum Pyrexia 10.3 Thromboembolic Disorders: DVT, Pulmonary Embolism & Septic Pelvic Thrombophlebitis 10.4 Perinatal Mood & Anxiety Disorders: Postpartum Blues, PPD, Anxiety & Postpartum Psychosis 10.5 Lactation Physiology, Breastfeeding Complications, Engorgement & Medication Safety

12 Chapter 11: Newborn Care, Transition & Clinical Assessment

11.1 Neonatal Physiologic Transition & Cardiorespiratory Adaptation 11.2 Immediate Newborn Care, Apgar Scoring & Delivery Room Stabilization 11.3 Newborn Thermoregulation & Pathophysiology of Cold Stress 11.4 Gestational Age & Neonatal Growth Assessment 11.5 Comprehensive Newborn Head-to-Toe Examination & Normal Variants

13 Chapter 12: Newborn Complications, Resuscitation & High-Acuity Management

12.1 Neonatal Resuscitation Program (NRP 8th Edition) & Delivery Room Resuscitation 12.2 Neonatal Glucose Homeostasis, Hypoglycemia Screening & Clinical Management 12.3 Neonatal Hyperbilirubinemia, Bilirubin Metabolism & Phototherapy Protocols 12.4 Neonatal Respiratory Distress: TTN, RDS, Meconium Aspiration & Persistent Pulmonary Hypertension (PPHN) 12.5 Neonatal Sepsis, Congenital Infections & Neonatal Abstinence Syndrome (NAS/NOWS)

14 Chapter 13: Professional Practice, Legal-Ethical Frameworks, Patient Safety & Quality Improvement

13.1 Legal Aspects of Perinatal Nursing & High-Risk Documentation Standards 13.2 Ethical Principles in Perinatal Care & Maternal-Fetal Conflicts 13.3 Quality Improvement, Perinatal Safety Initiatives & AIM Bundles 13.4 Patient Safety Culture, Team Communication & Clinical Escalation 13.5 Evidence-Based Practice, Research Utilization & Perinatal Guidelines

1.4 Maternal Cardiac and Respiratory Disorders

Key Takeaways Explain This Topic AI

Maternal hemodynamic changes peak during three critical windows: late second trimester (28-32 weeks), the second stage of labor (uterine contractions autotransfuse 300-500 mL into central circulation), and the immediate 24-48 hours postpartum (cardiac output surges 60-80% above pre-pregnancy baseline).

World Health Organization (WHO) Pregnancy Cardiac Risk Class IV conditions—including severe pulmonary arterial hypertension, Eisenmenger syndrome, severe symptomatic aortic stenosis, and peripartum cardiomyopathy with residual left ventricular dysfunction (LVEF <30-40%)—carry 30-50% maternal mortality and represent contraindications to pregnancy.

Inpatient intrapartum nursing care for cardiac patients requires lateral positioning, early continuous epidural analgesia to blunt sympathetic surges and tachycardia, fluid restriction (<1,000 mL/24h or 50-75 mL/hr), and passive second-stage descent with assisted operative delivery (forceps/vacuum) to avoid maternal pushing.

In pregnant asthmatics, acute bronchospasm must be treated aggressively while strictly avoiding bronchoconstrictive medications: Carboprost tromethamine (Hemabate) is contraindicated due to severe bronchospasm, and Methylergonovine (Methergine) and Indomethacin must be avoided in aspirin-sensitive respiratory disease.

To minimize spinal/epidural hematoma risk, neuraxial anesthesia requires holding prophylactic Low Molecular Weight Heparin (LMWH) for ≥12 hours, therapeutic LMWH for ≥24 hours, and IV therapeutic Unfractionated Heparin (UFH) for 4-6 hours with a confirmed normal aPTT.

Last updated: August 2026

Hemodynamic Physiology of Pregnancy and High-Risk Windows

Normal pregnancy induces profound, progressive cardiovascular remodeling to satisfy the metabolic demands of the growing uteroplacental unit:

Total Blood Volume: Increases by 40% to 50% (1,200–1,600 mL), with plasma volume expanding proportionally more than red blood cell mass.

Cardiac Output (CO): Increases by 30% to 50% above baseline, driven initially by an increase in stroke volume (20–30%) and subsequently by an increase in resting heart rate (15–20 beats per minute).

Systemic Vascular Resistance (SVR): Decreases by 20% to 30% due to the low-resistance uteroplacental shunt and vasodilatory effects of progesterone, prostacyclin, and nitric oxide.

The Three High-Risk Windows for Cardiac Decompensation

Maternal cardiac decompensation characteristically occurs during three peak hemodynamic stress intervals:

28 to 32 Weeks Gestation: Plasma volume expansion reaches its absolute maximum peak.

Labor and Delivery (Second Stage): Every uterine contraction expels 300 to 500 mL of blood from the uteroplacental bed into the central maternal circulation (autotransfusion), increasing venous return and transiently elevating cardiac output by 30% to 50% . Maternal pushing (Valsalva maneuver) further causes dramatic swings in intrathoracic pressure, preload, and arterial blood pressure.

Immediate Postpartum (First 24–48 Hours): Following placental delivery, vena caval compression is completely relieved, and dramatic uterine involution autotransfuses up to 500 to 1,000 mL of blood into maternal systemic circulation. Simultaneously, interstitial edema mobilizes rapidly back into the intravascular space, driving cardiac output up to 60% to 80% above baseline —the single highest period of maternal cardiac arrest and pulmonary edema. +-------------------------------------------------------------------------------------------------------------------+

| CARDIAC OUTPUT PROFILE ACROSS PREGNANCY & LABOR |

+-------------------------------------------------------------------------------------------------------------------+

  • Gestational Phase Cardiac Output Change Relative to Baseline Non-Pregnant State
  • ---------------- -------------------------------------------------------------
  • Baseline Non-Pregnant 100% (approx. 4.5 - 5.0 L/min)
  • Early 1st Trimester (12 wk) ↑ 10 - 15% (5.5 L/min)
  • Peak Antepartum (28 - 32 wk) ↑ 40 - 50% (6.5 - 7.0 L/min) [Peak Volume Load]
  • Labor: Early 1st Stage ↑ 15 - 20% above antepartum baseline
  • Labor: Active 2nd Stage (Contraction) ↑ 45 - 50% above antepartum baseline (8.5 - 9.5 L/min)
  • Immediate Postpartum (10 - 60 min) ↑ 60 - 80% ABOVE BASELINE (Up to 10.0 L/min) [HIGHEST DECOMPENSATION RISK]
  • Postpartum Day 2 to 7 Gradual decline toward pre-pregnancy values (normalizes by 6-12 wk)

+-------------------------------------------------------------------------------------------------------------------+

Cardiac Risk Stratification: NYHA and Modified WHO Systems

Cardiac disease is currently the leading cause of indirect maternal mortality in the United States. Risk assessment combines the New York Heart Association (NYHA) Functional Classification with the disease-specific Modified World Health Organization (WHO) Pregnancy Cardiac Risk Classification :

NYHA Functional Classification

Class I: Uncompromised; ordinary physical activity does not cause undue fatigue, palpitations, dyspnea, or anginal pain.

Class II: Slightly compromised; comfortable at rest, but ordinary physical activity results in fatigue, dyspnea, or angina.

Class III: Markedly compromised; comfortable at rest, but less than ordinary activity causes fatigue, dyspnea, or palpitations.

Class IV: Severely compromised; inability to perform any physical activity without discomfort; symptoms of cardiac insufficiency or angina present even at rest.

Modified WHO Pregnancy Cardiac Risk Classification +-------------------------------------------------------------------------------------------------------------------+

| MODIFIED WHO PREGNANCY CARDIAC RISK CLASSIFICATION |

+-------------------------------------------------------------------------------------------------------------------+

  • WHO Risk Class Maternal Risk Profile Clinical Conditions Included
  • ------------- --------------------- ----------------------------
  • WHO Class I Extremely Low Risk - Mild pulmonary stenosis, patent ductus arteriosus (repaired)
  • (<1% morbidity) - Successfully repaired simple ASD / VSD

-------------------------------------------------------------------------------------------------------------------

  • WHO Class II / III Low-to-Moderate Risk - Unoperated ASD / VSD, repaired Tetralography of Fallot
  • (2 - 15% morbidity) - Mild left ventricular impairment, hypertrophic cardiomyopathy
  • Marfan syndrome without aortic dilation (<40 mm)

-------------------------------------------------------------------------------------------------------------------

  • WHO Class III High Risk - Mechanical heart valves (complex anticoagulation)
  • (19 - 27% morbidity) - Systemic right ventricle, Fontan circulation
  • Unrepaired cyanotic congenital heart disease

-------------------------------------------------------------------------------------------------------------------

  • WHO Class IV EXTREMELY HIGH RISK - Pulmonary Arterial Hypertension of any etiology (Eisenmenger)
  • (30 - 50% MORTALITY) - Severe systemic ventricular dysfunction (LVEF <30% or NYHA III-IV)
  • [PREGNANCY - Previous Peripartum Cardiomyopathy with residual LV impairment
  • CONTRAINDICATED] - Severe symptomatic aortic stenosis or severe mitral stenosis
  • Severe aortic dilation (>45 mm in Marfan syndrome or bicuspid valve)
  • Severe native coarctation of the aorta

+-------------------------------------------------------------------------------------------------------------------+

  • Specific Maternal Cardiac Disorders
  • 1. Mitral Stenosis (Rheumatic Heart Disease)

Pathophysiology: Fixed mechanical obstruction to left ventricular inflow. The physiologic tachycardia of pregnancy shortens diastolic filling time, causing massive elevation in left atrial pressures, pulmonary venous congestion, and sudden acute pulmonary edema. Atrial fibrillation can trigger catastrophic hemodynamic collapse.

Management: Maintain maternal heart rate <80 to 90 bpm using beta-1 selective blockers (Metoprolol). Avoid fluid overload.

2. Eisenmenger Syndrome and Pulmonary Arterial Hypertension (PAH)

Pathophysiology: Severe, irreversible pulmonary hypertension resulting in right-to-left or bidirectional shunting through a congenital cardiac defect (VSD, ASD, PDA). Maternal mortality is 30% to 50% .

Mechanism of Collapse: Any sudden drop in systemic vascular resistance (e.g., from blood loss, spinal anesthesia, or vasodilation) worsens the right-to-left shunt, inducing intractable cyanosis, hypoxemia, cardiovascular collapse, and sudden death.

3. Peripartum Cardiomyopathy (PPCM)

Definition: An idiopathic cardiomyopathy presenting with heart failure secondary to left ventricular systolic dysfunction ( Left Ventricular Ejection Fraction [LVEF] <45% ) developing during the last month of pregnancy or within 5 months postpartum in a woman without prior heart disease.

Risk Factors: Advanced maternal age, multiparity, African-American ancestry, multiple gestation, chronic hypertension, and preeclampsia.

Clinical Presentation: Rapidly progressive dyspnea, orthopnea, paroxysmal nocturnal dyspnea, cough, peripheral edema, elevated B-type Natriuretic Peptide (BNP), and cardiomegaly on chest X-ray.

Medical Management: Standard heart failure regimen tailored for pregnancy (diuretics [furosemide], beta-blockers [carvedilol/metoprolol succinate], hydralazine and nitrates for afterload reduction; ACE inhibitors and ARBs are strictly contraindicated antepartum but are first-line postpartum; Bromocriptine may be considered to block prolactin cleavage products; therapeutic anticoagulation is indicated due to high thromboembolic risk when LVEF <35%).

Prognosis & Future Pregnancies: If LVEF does not normalize (>50–55%), subsequent pregnancy carries a 30% to 50% risk of recurrence, irreversible heart failure, and death .

Inpatient Nursing Bundle for Intrapartum Cardiac Care +-------------------------------------------------------------------------------------------------------------------+

| INTRAPARTUM CARDIAC NURSING BUNDLE PROTOCOL |

+-------------------------------------------------------------------------------------------------------------------+

1. POSITIONING: - Maintain continuous Left Lateral Decubitus tilt to maximize IVC blood flow and avoid

sudden preload swings.

-------------------------------------------------------------------------------------------------------------------

2. ANESTHESIA: - Early continuous lumbar epidural analgesia (slow, fractionated titration) to blunt

sympathetic catecholamine surges, tachycardia, and cardiac workload.

-------------------------------------------------------------------------------------------------------------------

3. FLUID BALANCE: - Strict fluid restriction: Total intake limited to 50 - 75 mL/hour (<1,000 mL/24h).

- Continuous hourly Foley output monitoring; avoid rapid fluid boluses during epidural placement.

-------------------------------------------------------------------------------------------------------------------

4. SECOND STAGE: - "LABORING DOWN" (Passive Descent): Allow uterine contractions to move fetal head down to perineum.

- AVOID prolonged Valsalva pushing.

- ELECTIVE OPERATIVE VAGINAL DELIVERY (Low Forceps or Vacuum) to shorten/eliminate 2nd stage.

-------------------------------------------------------------------------------------------------------------------

5. POSTPARTUM (STAGE 3): - Administer slow dilute IV oxytocin infusion (e.g., 20 units in 500 mL crystalloid over 1-2 hr).

- AVOID RAPID IV PUSH OXYTOCIN (causes severe hypotension, peripheral vasodilation, & tachycardia).

- STRICT CONTRAINDICATIONS: Methylergonovine (Methergine) is contraindicated (causes severe

vasoconstriction/hypertension); Carboprost (Hemabate) is contraindicated (causes pulmonary HTN).

+-------------------------------------------------------------------------------------------------------------------+

  • Maternal Respiratory Disorders and Critical Medication Contraindications
  • Asthma Management in Inpatient Obstetrics

Asthma complicates 4% to 8% of pregnancies. As a clinical rule of thumb, "one-third improve, one-third worsen, and one-third remain unchanged." Maintenance of maternal oxygenation is vital; maternal PaO2 must be maintained >70 mmHg or SpO2 >= 95% to ensure an adequate maternal-to-fetal oxygen diffusion gradient across the placenta.

Stepwise Pharmacotherapy: Inhaled short-acting beta-agonists (Albuterol) are safe first-line rescue agents; Inhaled Corticosteroids (Budesonide preferred) must be continued without interruption throughout labor; systemic corticosteroids (oral Prednisone or IV Methylprednisolone) are indicated for moderate-to-severe acute exacerbations.

Critical Obstetric Medication Contraindications in Asthmatics:

Carboprost Tromethamine (Hemabate / PGF2-alpha): STRICTLY CONTRAINDICATED. Potent smooth muscle constrictor that induces immediate, life-threatening bronchospasm and arterial desaturation.

Methylergonovine (Methergine): Use with extreme caution; can trigger bronchospasm in patients with aspirin-exacerbated respiratory disease (AERD / Samter's triad).

Indomethacin (NSAID Tocolytic): Contraindicated in aspirin-sensitive asthmatics due to cyclooxygenase inhibition shunting arachidonic acid into the leukotriene pathway, inducing severe bronchospasm. +-------------------------------------------------------------------------------------------------------------------+

| OBSTETRIC DRUG SAFETY & CONTRAINDICATIONS IN CARDIOPULMONARY DISEASE |

+-------------------------------------------------------------------------------------------------------------------+

  • Drug Name (Brand) Obstetric Indication Cardiopulmonary Safety / Contraindications
  • ---------------- -------------------- ------------------------------------------
  • Carboprost (Hemabate) Postpartum Hemorrhage ★ STRICTLY CONTRAINDICATED IN ASTHMA (Induces severe bronchospasm)
  • ★ CAUTION IN CARDIAC DISEASE (Increases pulmonary vascular resistance)

-------------------------------------------------------------------------------------------------------------------

  • Methylergonovine Postpartum Hemorrhage ★ STRICTLY CONTRAINDICATED IN HYPERTENSION / PREECLAMPSIA
  • (Methergine) ★ CONTRAINDICATED IN CORONARY DISEASE (Severe vasoconstriction)

-------------------------------------------------------------------------------------------------------------------

Terbutaline (Brethine) Tocolysis / Tachysystole ★ CONTRAINDICATED IN MATERNAL CARDIAC DISEASE (Severe tachycardia)

★ Black box warning: Do not use for prolonged tocolysis (>48-72h)

-------------------------------------------------------------------------------------------------------------------

Oxytocin (Pitocin) Labor Induction / PPH ★ AVOID RAPID IV BOLUS (Causes hypotension, flushing, and tachycardia)

★ Administer as slow, controlled dilute IV infusion only

+-------------------------------------------------------------------------------------------------------------------+

Anticoagulation Timing and Neuraxial Anesthesia Protocols

Pregnancy increases the risk of venous thromboembolism (VTE) 4- to 5-fold due to hypercoagulability, venous stasis, and vascular injury. Deep vein thrombosis (DVT) develops predominantly in the left lower extremity (80% of cases) due to compression of the left common iliac vein by the right common iliac artery and the gravid uterus.

Low Molecular Weight Heparin (LMWH, e.g., Enoxaparin) is the anticoagulant of choice during pregnancy because it does not cross the placenta and has a lower risk of heparin-induced thrombocytopenia (HIT) and osteoporosis than Unfractionated Heparin (UFH). However, to prevent spinal/epidural hematoma —which can cause permanent paraplegia—strict timing intervals must be maintained before placing or removing neuraxial needles/catheters: +-------------------------------------------------------------------------------------------------------------------+

| NEURAXIAL ANESTHESIA & ANTICOAGULATION TIMING GUIDELINES (ASRA / ACOG) |

+-------------------------------------------------------------------------------------------------------------------+

  • Anticoagulant Regimen Dose Classification Mandatory Hold Time Before Neuraxial Placement
  • -------------------- ------------------- ----------------------------------------------
  • LMWH (Enoxaparin) Prophylactic Dose HOLD FOR AT LEAST 12 HOURS
  • (e.g., 40 mg SC daily) (Do not place needle/catheter until 12 hr elapsed)

-------------------------------------------------------------------------------------------------------------------

  • LMWH (Enoxaparin) Therapeutic Dose HOLD FOR AT LEAST 24 HOURS
  • (e.g., 1 mg/kg SC q12h) (Do not place needle/catheter until 24 hr elapsed)

-------------------------------------------------------------------------------------------------------------------

  • Unfractionated Heparin Intravenous Therapeutic HOLD FOR 4 TO 6 HOURS
  • (UFH) Continuous Infusion (Confirm normal aPTT before neuraxial needle placement)

-------------------------------------------------------------------------------------------------------------------

  • Unfractionated Heparin High-Dose Prophylactic HOLD FOR 12 HOURS
  • (UFH) (>10,000 units SC/dose) (or check aPTT)

+-------------------------------------------------------------------------------------------------------------------+

  • | Catheter Removal & Resumption Protocols: |
  • | - Restart Prophylactic LMWH: Wait at least 4 hours AFTER epidural catheter removal. |

| - Restart Therapeutic LMWH: Wait at least 24 hours AFTER catheter removal and at least 24 hours post-cesarean. |

+-------------------------------------------------------------------------------------------------------------------+